Jocelyn Uriostegui, PA
Endocrinology, Diabetes & Metabolism · Annapolis, MDNPI 1912475633
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,829, 2.6 times the $700 reported in 2021.
Across 341 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$922
- Xeris Pharmaceuticals, Inc.$564
- Sanofi-aventis U.S. LLC$557
- AstraZeneca$392
- Amneal Pharmaceuticals LLC$318
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,103100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 72 | $1,462 |
| Novo Nordisk | 53 | $922 |
| Xeris Pharmaceuticals, Inc. | 22 | $564 |
| Sanofi-aventis U.S. LLC | 24 | $557 |
| AstraZeneca(2 entities) | 18 | $392 |
| Amneal Pharmaceuticals LLC | 17 | $318 |
| Boehringer Ingelheim | 14 | $287 |
| Dexcom, Inc. | 13 | $273 |
| Amgen | 14 | $265 |
| Bayer | 13 | $254 |
| Insulet Corporation | 9 | $214 |
| Radius Health, Inc. | 7 | $177 |
| Cequr Corporation | 4 | $176 |
| Amphastar Pharmaceuticals, Inc. | 8 | $147 |
| Corcept Therapeutics | 4 | $119 |
| Medtronic | 6 | $109 |
| Tandem Diabetes Care, Inc. | 5 | $105 |
| AbbVie | 4 | $82 |
| IBSA Pharma Inc. | 4 | $76 |
| Abbott | 3 | $61 |
| Embecta Corp. | 2 | $52 |
| BD | 2 | $49 |
| Verity Pharmaceuticals Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $39 |
| Nevro Corp. | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Novartis | 1 | $32 |
| Mannkind Corporation | 2 | $32 |
| Enterra Medical, Inc. | 1 | $30 |
| Merck | 2 | $30 |
| Globus Medical | 2 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Pfizer | 1 | $24 |
| Lifescan, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| RGH Enterprises LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE PFS$231
How this compares
$7,115 in reported general payments places this provider in the 75th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 157 | $302,875 |
| JardianceEmpagliflozin | 42 | $63,914 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 60 | $48,395 |
| TrulicityDulaglutide | 19 | $37,797 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $34,300 |
| MounjaroTirzepatide | 16 | $25,123 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $24,325 |
| FarxigaDapagliflozin Propanediol | 15 | $23,225 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,151 |
| JanuviaSitagliptin Phosphate | 15 | $9,542 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $9,000 |
| Novolog FlexpenInsulin Aspart | 21 | $8,579 |
| SynthroidLevothyroxine Sodium | 46 | $4,527 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $4,305 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 47 | $4,220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $922 | $302,875157 claims |
| Boehringer IngelheimJardiance | $287 | $63,91442 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,462 | $62,92035 claims |
| AstraZenecaFarxiga | $392 | $23,22515 claims |
| MerckJanuvia | $30 | $9,54215 claims |
| AbbVieSynthroid | $82 | $4,52746 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $318 | $3,018258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Annapolis
- Eyob MakonnenAnnapolis$205K
- Darshana PurohitAnnapolis$25K
- Barbara OnumahAnnapolis$12K
- Kavita IyengarAnnapolis$9K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.